Takeda Pharmaceutical (NYSE:TAK) Reaches New 52-Week High – Here’s What Happened

Takeda Pharmaceutical Co. (NYSE:TAK)’s stock price reached a new 52-week high on Thursday. The company traded as high as $19.41 and last traded at $19.8380, with a volume of 21,418 shares. The stock had previously closed at $19.01.

Analyst Ratings Changes

A number of brokerages have issued reports on TAK. Weiss Ratings upgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Zacks Research lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 1st. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

The company has a 50 day moving average price of $18.27 and a 200 day moving average price of $17.26. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The firm has a market cap of $63.61 billion, a PE ratio of 58.48 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $7.50 billion for the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Takeda Pharmaceutical news, insider Giles Platford sold 31,083 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30. Following the sale, the insider owned 315,838 shares in the company, valued at approximately $5,400,829.80. This represents a 8.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Anne Furney sold 30,868 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $527,842.80. Following the completion of the sale, the general counsel owned 204,298 shares in the company, valued at $3,493,495.80. This represents a 13.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 627,457 shares of company stock valued at $10,981,175. Company insiders own 0.04% of the company’s stock.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds have recently bought and sold shares of TAK. SHP Wealth Management acquired a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $42,000. Rockefeller Capital Management L.P. increased its stake in Takeda Pharmaceutical by 30.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company’s stock valued at $81,000 after buying an additional 1,215 shares during the period. Walkner Condon Financial Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $186,000. Valeo Financial Advisors LLC acquired a new position in shares of Takeda Pharmaceutical during the second quarter valued at approximately $163,000. Finally, Pure Financial Advisors LLC bought a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $164,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder.